Anmelden

Jeffrey V. Leyton

Department of Nuclear Medicine and Radiobiology,
Sherbrooke Molecular Imaging Center (CIMS)

Université de Sherbrooke

BIOGRAPHY

Jeffrey V. Leyton has not added Biography.

If you are Jeffrey V. Leyton and would like to personalize this page please email our Author Liaison for assistance.

PUBLICATIONS

The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.

Nuclear medicine and biology May-Jun, 2014 | Pubmed ID: 24637100

Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine Apr, 2016 | Pubmed ID: 26748017

ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation.

Molecular pharmaceutics Jun, 2016 | Pubmed ID: 27112376

Development of a Novel Covalent Folate-Albumin-Photosensitizer Conjugate.

Photochemistry and photobiology 07, 2016 | Pubmed ID: 27221219

Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.

Nuclear medicine and biology Oct, 2016 | Pubmed ID: 27497632

BODIPY-17α-ethynylestradiol conjugates: Synthesis, fluorescence properties and receptor binding affinities.

Bioorganic & medicinal chemistry letters Feb, 2017 | Pubmed ID: 28049591

Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.

Oncoimmunology , 2017 | Pubmed ID: 29123949

INSTITUTIONS

Université de Sherbrooke

Sherbrooke Institute of Pharmacology

JOVE ARTICLES

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Simon Beaudoin¹,

Michel Paquette¹,

Laurent Fafard-Couture¹,

Mylene A. Tremblay¹,

Roger Lecomte^1,2,3,

Brigitte Guérin^1,2,3,

Jeffrey V. Leyton^1,2,3

¹Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke,

²Sherbrooke Molecular Imaging Center (CIMS), Université de Sherbrooke,

³, Sherbrooke Institute of Pharmacology

Bioengineering

Datenschutz

Nutzungsbedingungen

Richtlinien

Kontakt

BIBLIOTHEKS-EMPFEHLUNG

JoVE-Newsletter

Forschung

JoVE Journal
Methodensammlungen
JoVE Encyclopedia of Experiments
Archiv

Lehre

JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Playlist
Faculty Site

Autoren

Übersicht
Veröffentlichungsprozess
Redaktionsausschuss
Umfang und Richtlinien
Peer Review
Häufig gestellte Fragen
Einreichen

Bibliothekare

Übersicht
Erfahrungsberichte
Lizenzen
Zugang
Ressourcen
Bibliotheksbeirat
Häufig gestellte Fragen

ÜBER JoVE

Übersicht
Geschäftsführung
Blog
JoVE Help Center
JoVE Sitemap

Wir verwenden Cookies, um Ihre Erfahrung auf unserer Website zu verbessern.

Indem Sie unsere Website weiterhin nutzen oder auf „Weiter“ klicken, stimmen Sie zu, unsere Cookies zu akzeptieren.

Weitere Informationen

Jeffrey V. Leyton

Department of Nuclear Medicine and Radiobiology,Sherbrooke Molecular Imaging Center (CIMS)

Université de Sherbrooke

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Department of Nuclear Medicine and Radiobiology,
Sherbrooke Molecular Imaging Center (CIMS)